WMT

131.04

+3.13%↑

COST

1,008.21

+1.82%↑

PG

146.72

+0.02%↑

PM

165.14

+1.23%↑

PEP

157.72

+1.79%↑

WMT

131.04

+3.13%↑

COST

1,008.21

+1.82%↑

PG

146.72

+0.02%↑

PM

165.14

+1.23%↑

PEP

157.72

+1.79%↑

WMT

131.04

+3.13%↑

COST

1,008.21

+1.82%↑

PG

146.72

+0.02%↑

PM

165.14

+1.23%↑

PEP

157.72

+1.79%↑

WMT

131.04

+3.13%↑

COST

1,008.21

+1.82%↑

PG

146.72

+0.02%↑

PM

165.14

+1.23%↑

PEP

157.72

+1.79%↑

WMT

131.04

+3.13%↑

COST

1,008.21

+1.82%↑

PG

146.72

+0.02%↑

PM

165.14

+1.23%↑

PEP

157.72

+1.79%↑

Search

Lifecore Biomedical Inc

Open

SectorConsumer defensive

5.03 0.8

Overview

Share price change

24h

Current

Min

4.84

Max

5.08

Key metrics

By Trading Economics

Income

-7.9M

-10M

Sales

-5.3M

31M

Profit margin

-32.116

Employees

400

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+30.27% upside

Dividends

By Dow Jones

Next Earnings

10 cze 2026

Market Stats

By TradingEconomics

Market Cap

-81M

160M

Previous open

4.23

Previous close

5.03

News Sentiment

By Acuity

33%

67%

45 / 131 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2026, 23:53 UTC

Earnings

Naver Posts Weaker First-Quarter Earnings

29 kwi 2026, 23:41 UTC

Hot Stocks

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 kwi 2026, 23:55 UTC

Earnings

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 kwi 2026, 23:54 UTC

Earnings

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 kwi 2026, 23:52 UTC

Earnings

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 kwi 2026, 23:51 UTC

Earnings

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 kwi 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan 1Q Net CNY1.70B, Down 14%

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan: Power Generation Down 2.9% as of End-March

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss Narrows>000002.SZ

29 kwi 2026, 23:18 UTC

Earnings

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 kwi 2026, 23:17 UTC

Earnings

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 kwi 2026, 23:13 UTC

Earnings

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 kwi 2026, 23:12 UTC

Earnings

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 kwi 2026, 23:04 UTC

Earnings

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 kwi 2026, 23:04 UTC

Earnings

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Price Target

By TipRanks

30.27% upside

12 Months Forecast

Average 6.67 USD  30.27%

High 9 USD

Low 5 USD

Based on 4 Wall Street analysts offering 12 month price targets forLifecore Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Sentiment

By Acuity

45 / 131 Ranking in Consumer defensive

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat